The biomarker is an important step toward understanding and treating one of the most devastating symptoms of schizophrenia.
Researchers have found that treatment with very low doses of a dopamine-1 receptor (D1R) agonist was not effective in reducing the cognitive and negative symptoms of schizophrenia.
In studies in mice, Zuckerman Institute researchers have discovered a way to restore memory deficits found in schizophrenia by regrowing lost neuronal connections.
A new computational analysis identifies gene networks involved in schizophrenia -- and a connection with autism.
As pharma retreats from developing new drugs for mental disorders, a new Columbia/NYSPI initiative is stepping in.